Tumor-to-blood ratio for assessment of fibroblast activation protein receptor density in pancreatic cancer using [68Ga]Ga-FAPI-04

Xia N, Yang N, Shan Q, et al. HNRNPC regulates RhoA to induce DNA damage repair and cancer-associated fibroblast activation causing radiation resistance in pancreatic cancer. J Cell Mol Med. 2022;26:2322–36.

Article  PubMed  PubMed Central  Google Scholar 

Ogawa Y, Masugi Y, Abe T, et al. Three distinct stroma types in human pancreatic cancer identified by image analysis of fibroblast subpopulations and collagen. Clin Cancer Res. 2021;27:107–19.

Article  PubMed  Google Scholar 

Shi M, Yu DH, Chen Y, et al. Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance. World J Gastroenterol. 2012;18:840–6.

Article  PubMed  PubMed Central  Google Scholar 

Lindner T, Loktev A, Altmann A, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59:1415–22.

Article  PubMed  Google Scholar 

Loktev A, Lindner T, Mier W, et al. A tumor-imaging method targeting cancer-associated fibroblasts. J Nucl Med. 2018;59:1423–9.

Article  PubMed  PubMed Central  Google Scholar 

Rohrich M, Naumann P, Giesel FL, et al. Impact of (68)Ga-FAPI PET/CT Imaging on the therapeutic management of primary and recurrent pancreatic ductal adenocarcinomas. J Nucl Med. 2021;62:779–86.

Article  PubMed  PubMed Central  Google Scholar 

Zhang Z, Jia G, Pan G, et al. Comparison of the diagnostic efficacy of (68) Ga-FAPI-04 PET/MR and (18)F-FDG PET/CT in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging. 2022; 49:2877–88.

Baum RP, Schuchardt C, Singh A, et al. Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas using (177)Lu-FAP-2286: first-in-humans results. J Nucl Med. 2022;63:415–23.

Article  PubMed  PubMed Central  Google Scholar 

Ilan E, Velikyan I, Sandstrom M, Sundin A, Lubberink M. Tumor-to-blood ratio for assessment of somatostatin receptor density in neuroendocrine tumors using (68)Ga-DOTATOC and (68)Ga-DOTATATE. J Nucl Med. 2020;61:217–21.

Article  PubMed  Google Scholar 

Gabriel M, Oberauer A, Dobrozemsky G, et al. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. J Nucl Med. 2009;50:1427–34.

Article  PubMed  Google Scholar 

Haug AR, Auernhammer CJ, Wangler B, et al. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med. 2010;51:1349–56.

Article  PubMed  Google Scholar 

Gunn RN, Gunn SR, Cunningham VJ. Positron emission tomography compartmental models. J Cereb Blood Flow Metab. 2001;21:635–52.

Article  PubMed  Google Scholar 

Ding W, Yu J, Zheng C, et al. Machine Learning-based noninvasive quantification of single-imaging session dual-tracer (18)F-FDG and (68)Ga-DOTATATE dynamic PET-CT in oncology. IEEE Trans Med Imaging. 2022;41:347–59.

Article  PubMed  Google Scholar 

Liu M, Paranjpe MD, Zhou X, et al. Sex modulates the ApoE epsilon4 effect on brain tau deposition measured by (18)F-AV-1451 PET in individuals with mild cognitive impairment. Theranostics. 2019;9:4959–70.

Article  PubMed  PubMed Central  Google Scholar 

Zhao Q, Chen X, Zhou Y. Quantitative multimodal multiparametric imaging in Alzheimer's disease. Brain Inform. 2016;3:29–37.

Article  PubMed  PubMed Central  Google Scholar 

Zhou Y, Ye W, Brasic JR, Wong DF. Multi-graphical analysis of dynamic PET. Neuroimage. 2010;49:2947–57.

Article  PubMed  Google Scholar 

Zhou Y, Endres CJ, Brasic JR, Huang SC, Wong DF. Linear regression with spatial constraint to generate parametric images of ligand-receptor dynamic PET studies with a simplified reference tissue model. Neuroimage. 2003;18:975–89.

Article  PubMed  Google Scholar 

Lang M, Spektor AM, Hielscher T, et al. Static and dynamic (68)Ga-FAPI PET/CT for the detection of malignant transformation of intraductal papillary mucinous neoplasia of the pancreas. J Nucl Med. 2022. https://doi.org/10.2967/jnumed.122.264361.

Zhang X, Xie Z, Berg E, et al. Total-body dynamic reconstruction and parametric imaging on the uEXPLORER. J Nucl Med. 2020;61:285–91.

Article  PubMed  PubMed Central  Google Scholar 

Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27:1533–9.

Article  PubMed  Google Scholar 

Koopman T, Verburg N, Schuit RC, et al. Quantification of O-(2-[(18)F]fluoroethyl)-L-tyrosine kinetics in glioma. EJNMMI Res. 2018;8:72.

Article  PubMed  PubMed Central  Google Scholar 

Ringheim A, Campos Neto GC, Anazodo U, et al. Kinetic modeling of (68)Ga-PSMA-11 and validation of simplified methods for quantification in primary prostate cancer patients. EJNMMI Res. 2020;10:12.

Article  PubMed  PubMed Central  Google Scholar 

Slaets D, De Vos F. Comparison between kinetic modelling and graphical analysis for the quantification of [18F]fluoromethylcholine uptake in mice. EJNMMI Res. 2013;3:66.

Article  PubMed  PubMed Central  Google Scholar 

Dendl K, Schlittenhardt J, Staudinger F, et al. The role of fibroblast activation protein ligands in oncologic PET imaging. PET Clin. 2021;16:341–51.

Article  PubMed  Google Scholar 

Coughlin JM, Slania S, Du Y, et al. (18)F-XTRA PET for enhanced imaging of the extrathalamic alpha4beta2 nicotinic acetylcholine receptor. J Nucl Med. 2018;59:1603-1608.

Iqbal R, Kramer GM, Frings V, et al. Validation of [(18)F]FLT as a perfusion-independent imaging biomarker of tumour response in EGFR-mutated NSCLC patients undergoing treatment with an EGFR tyrosine kinase inhibitor. EJNMMI Res. 2018;8:22.

Article  PubMed  PubMed Central  Google Scholar 

Pure E, Blomberg R. Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics. Oncogene. 2018;37:4343–57.

Article  PubMed  PubMed Central  Google Scholar 

Kilvaer TK, Khanehkenari MR, Hellevik T, et al. Cancer associated fibroblasts in Stage I-IIIA NSCLC: prognostic impact and their correlations with tumor molecular markers. PLoS ONE. 2015;10:e0134965.

Article  PubMed  PubMed Central  Google Scholar 

留言 (0)

沒有登入
gif